Vitruvias Therapeutics Inc. Enters into a Semi-Solid (Topical) Licensing Agreement with Hong Kong-Based Bright Future

AUBURN, Ala. & HONG KONG–(BUSINESS WIRE)–Vitruvias Therapeutics Inc., an Auburn, Alabama-based finished-dose
generic drug company, has announced it has entered into a collaborative
development agreement with a Hong Kong-based pharmaceutical company,
Bright Future Pharmaceutical Lab Ltd, to develop a portfolio of
semi-solids to be marketed in the United States and China. U.S.
distribution will be handled by Vitruvias and Bright Future will be
responsible for China and other agreed upon Asian territories. The
products will be manufactured by Bright Future’s newly constructed unit
at its Hong Kong site specifically designed for producing products in
regulated markets.

“We are elated to have found a partner with the resources, rich history
of success in the complex Chinese markets, and philosophical belief
system that matches our own,” said Carl Whatley, Chairman and CEO of
Vitruvias. “Bright Future has proven themselves to be an
entrepreneurially-driven company with regards to their desire to become
a global player in the world of dermatology, and we are very fortunate
to have found such a partner.” With their product development expertise,
manufacturing sophistication and the ability to reach both large and
small markets in China, Bright Future’s dermatology portfolio is
currently the most widely prescribed brand by Chinese dermatologists.

The Founder and Chairman of the Bright Future Group, Mr. Chan Chak
Yeung, said, “We are looking forward to working with the Vitruvias team
to achieve our mutual goals. Their experience in the U.S. will help us
implement our next objective of attaining an international presence in
the field of dermatology. We also hope to work with Vitruvias to
leverage our strengths in the production of other dosage forms as we
pursue a broader collaboration.”

About Vitruvias Therapeutics

Vitruvias Therapeutics is a generic pharmaceutical company which
utilizes domestic and international partnerships to develop,
manufacture, and market generic products. Founded in the southern U.S.
in 2013, the company’s primary focus is on products in the generic
sterile injectable market, semi-solid market, and selected high-value
oral solids. The Company currently markets several generic products in
the U.S. The company received its first approval in September 2017 and
anticipates several additional ANDA applications will be filed during
2019. www.vitruvias.com

About Bright Future

Headquartered in Hong Kong, Bright Future Group is a leading
pharmaceutical company committed to developing affordable and reliable
generic medical solutions since 1993. Today, the company is the largest
PIC/S GMP certified pharmaceutical manufacturer in Hong Kong. With years
of development, it has also established subsidiary plants in Hong Kong,
Mainland China, the USA and Germany. Pursuing its long-term corporate
vision, 7,000 employees dedicate themselves to the research and
development, manufacturing and commercialization of generic medicines,
health supplements and daily necessities worldwide. It focuses on the
treatment of disorders for patients in the areas of dermatology,
orthopedics, respiratory, pediatrics, geriatric and gynecology. Bright
Future Group has strong international R&D teams in Hong Kong, New York,
as well as Haikou and Suzhou in China to support our network. The
company strives to fulfill their commitment, continuing to expand their
product portfolio to make a significant contribution locally and
globally. www.brightfuture.com.hk

Contacts

Carl Whatley
Chairman & CEO
Vitruvias Therapeutics Inc.
Phone
+1 (334) 329-5601
carl@vitruvias.com

Maggie Lau Wai Ching
Corporate Communications Manager
Bright
Future Group
Phone +852 2211 2447
ccm@brightfuture.com.hk